| Budder Siddiqui, MD | |
|
743 Spring St Ne, Gainesville, GA 30501-3715 | |
| (770) 219-9000 | |
| Not Available |
| Full Name | Budder Siddiqui |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 15 Years |
| Location | 743 Spring St Ne, Gainesville, Georgia |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366670051 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northeast Georgia Medical Center, Inc | Gainesville, GA | Hospital |
| Habersham County Medical Ctr | Demorest, GA | Hospital |
| Barrow Regional Medical Center | Winder, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Georgia Physicians Group Inc | 6901898386 | 646 |
News Archive
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.
Cold Spring Harbor Laboratory (CSHL) scientists recently led a team of researchers to study potential effects of space radiation on astronauts. The results of their study are revealing and will provide the foundation for ensuring the safety of crew members participating in long distance space travel.
Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
› Verified 8 days ago
| Entity Name | Au Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841230620 PECOS PAC ID: 9931013513 Enrollment ID: O20040107000188 |
News Archive
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.
Cold Spring Harbor Laboratory (CSHL) scientists recently led a team of researchers to study potential effects of space radiation on astronauts. The results of their study are revealing and will provide the foundation for ensuring the safety of crew members participating in long distance space travel.
Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
› Verified 8 days ago
| Entity Name | Augusta University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760559124 PECOS PAC ID: 0840188090 Enrollment ID: O20040309000453 |
News Archive
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.
Cold Spring Harbor Laboratory (CSHL) scientists recently led a team of researchers to study potential effects of space radiation on astronauts. The results of their study are revealing and will provide the foundation for ensuring the safety of crew members participating in long distance space travel.
Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
› Verified 8 days ago
| Entity Name | Northeast Georgia Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891745212 PECOS PAC ID: 6901898386 Enrollment ID: O20040402001277 |
News Archive
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.
Cold Spring Harbor Laboratory (CSHL) scientists recently led a team of researchers to study potential effects of space radiation on astronauts. The results of their study are revealing and will provide the foundation for ensuring the safety of crew members participating in long distance space travel.
Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Budder Siddiqui, MD Po Box 742616, Atlanta, GA 30374-2616 Ph: (770) 219-8420 | Budder Siddiqui, MD 743 Spring St Ne, Gainesville, GA 30501-3715 Ph: (770) 219-9000 |
News Archive
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.
A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.
Cold Spring Harbor Laboratory (CSHL) scientists recently led a team of researchers to study potential effects of space radiation on astronauts. The results of their study are revealing and will provide the foundation for ensuring the safety of crew members participating in long distance space travel.
Researchers from Brigham and Women's Hospital (BWH) have made a groundbreaking discovery that will shape the future of melanoma therapy. The team, led by Thomas S. Kupper, MD, chair of the BWH Department of Dermatology, and Rahul Purwar, PhD, found that high expression of a cell-signaling molecule, known as interleukin-9, in immune cells inhibits melanoma growth.
› Verified 8 days ago
James D Jackson, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 1285 Sims St, Gainesville, GA 30501 Phone: 770-219-8583 | |
Eileen Javellana, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 725 Jesse Jewell Pkwy Se, Gainesville, GA 30501 Phone: 678-207-4373 Fax: 770-533-4727 | |
Dr. Nitya S Chandra, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 S Enota Dr Ne Ste 100, Gainesville, GA 30501 Phone: 770-534-2020 Fax: 770-534-8025 | |
Dr. Lisa Armsrees Gillespie, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-219-8420 | |
Dr. Noelle Claudine Stanley, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 1211 Sherwood Park Dr Ne Ste B, Gainesville, GA 30501 Phone: 770-219-9179 | |
Kedric Naylor, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Gainesville, GA 30501 Phone: 770-219-9000 Fax: 770-538-7872 | |
Dr. William Nathan Blake, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 743 Spring St Ne, Ngpg Inpatient Medicine, Gainesville, GA 30501 Phone: 770-219-6000 Fax: 770-219-6021 |